Controversial drug decisions mount as FDA reduces public advisory meetings. Industry leaders say the adcomms can add transparency to the approval process.
By Lizzy Lawrence
More around STAT
In case you missed it
Brain tumor survivors are forcing a rethink of cancer care, Bloomberg
Cancer haunts neighbors of Canada's oil sands wastelands, New York Times
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.
